Woo, V., Shestakova, M. V., Orskov, C. and Ceriello, Antonio (2008) Targets and tactics : the relative importance of HbA(1c), fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. International Journal of Clinical Practice, Vol.62 (No.12). pp. 1935-1942. ISSN 1368-5031

Full text not available from this repository.

Abstract

The incidence of type 2 diabetes is reaching pandemic proportions, impacting patients and healthcare systems across the globe. Evidence suggests that a majority of patients are not achieving recommended blood glucose targets resulting in an increased risk of micro- and macro-vascular complications. To review literature on the significance of glycosylated haemoglobin (HbA(1c)), fasting plasma glucose (FPG) and postprandial plasma glucose (PPG), their inter-relationships and relative importance in the treatment of diabetes, and to provide practical guidance on effective monitoring of patients. Clinical guidelines on diabetes management and clinical and preclinical studies of glycaemic control identified through a publications database search were reviewed. Glycaemic control remains fundamental to the successful management of diabetes. HbA(1c) is the gold standard measure of glycaemic control but recent evidence suggests that postmeal hyperglycaemia also plays an important role in the aetiology of diabetes-associated complications and control of PPG levels is vital to the achievement of recommended HbA(1c) targets. The call for action on type 2 diabetes has never been more compelling; with a clear focus on strategies for glycaemic control, the impact of the diabetes pandemic can be limited.

Item Type:	Journal Item
Subjects:	Q Science > QP Physiology R Medicine > RC Internal medicine R Medicine > RS Pharmacy and materia medica
Divisions:	Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Non-insulin-dependent diabetes -- Treatment, Glycosylated hemoglobin -- Measurement
Journal or Publication Title:	International Journal of Clinical Practice
Publisher:	Wiley-Blackwell Publishing, Inc
ISSN:	1368-5031
Date:	December 2008
Volume:	Vol.62
Number:	No.12
Number of Pages:	8
Page Range:	pp. 1935-1942
Identification Number:	10.1111/j.1742-1241.2008.01941.x
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
References:	1 IDF. Diabetes Atlas, 3rd edn. 2006 http://www.eatlas.idf.org/. 2 Chuang LM, Tsai ST, Huang BY, Tai TY. The status of diabetes control in Asia – a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med 2002; 19: 978–85. 3 Liebl A, Neiss A, Spannheimer A et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany – results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002; 110: 10–6. 4 Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 531–7. 5 Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335–42. 6 American Diabetes Association. Standards of medical care in diabetes– 2008. Diabetes Care 2008; 31: S12–54. 7 UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53. 8 Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12. 9 Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005; 28: 2626–32. 10 Shiraiwa T, Kaneto H, Miyatsuka T et al. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005; 28: 2806–7. 11 Woerle HJ, Neumann C, Zschau S et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280–5. 12 Hirsch IB. Glycemic variability: it’s not just about A1C anymore! Diabetes Technol Ther 2005; 7: 780–3. 13 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881–5. 14 Ceriello A, Colagiuri S, Gerich J, Tuomilehto J. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 2008; 18: S17–33. 15 Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia 2004; 47: 1143–8. 16 Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007; 30: 2399–400. 17 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86. 18 The writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159–67. 19 The writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563–9. 20 Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med 2007; 24: 582–6. 21 Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–31. 22 Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17. 23 Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–7. 24 Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6. 25 Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233–40. 26 Caputo S, Pitocco D, Ruotolo V, Ghirlanda G. What is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA(1c) and overall blood glucose control? Diabetes Care 2001; 24: 2011. 27 Trovati M, Burzacca S, Mularoni E et al. A comparison of the predictive power for overall blood glucose control of a ‘good’ fasting level in type 2 diabetic patients on diet alone or with oral agents. Diabet Med 1992; 9: 134–7. 28 Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822–6. 29 ADA. Postprandial blood glucose. American Diabetes Association. Diabetes Care 2001; 24: 775–8. 30 Bonora E, Corrao G, Bagnardi V et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 846–54. 31 Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260–5. 32 Malone JK, Kerr LF, Campaigne BN et al. Combined therapy with insulin lispro Mix 75 ⁄ 25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034–44. 33 Malone JK, Bai S, Campaigne BN et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005; 22: 374–81. 34 The DECODE study group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397–405. 35 Esposito K, Ciotola M, Corleo D et al. Post-Meal Glucose Peaks at Home Associate with Carotid Intima-Media Thickness in Type 2 Diabetes. J Clin Endocrinol Metab 2008; 93: 2639–46. 36 Monnier L, Colette C, Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006; 12 (Suppl. 1): 42–6. 37 Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146–54. 38 Ceriello A, Quagliaro L, Catone B et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439–43. 39 Ceriello A, Cavarape A, Martinelli L et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21: 171–5. 40 Hanefeld M, Chiasson JL, Koehler C et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073–8. 41 Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214–9. 42 Mita T, Watada H, Shimizu T et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007; 27: 2456–62. 43 Yokoyama H, Kannno S, Ishimura I, Node K. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 1458– 63. 44 Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486–94. 45 Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45: S23–8. 46 Kilpatrick E, Ørskov C, Berntorp K, Koblik T. HbA1c: The gap Between Guidelines and Clinical Reality Across Eight Countries. Amsterdam, The Netherlands: EASD, 2007. 47 IDF Clinical Guidelines Taskforce. International Diabetes Federation Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23: 579–93. 48 Karter AJ, Ackerson LM, Darbinian JA et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001; 111: 1–9. 49 Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–21. 50 Kazda C, Hulstrunk H, Helsberg K et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complicat 2006; 20: 145–52. 51 Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716–30. 52 Chiasson JL, Naditch L. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001; 24: 989–94. 53 Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27: 1265–70. 54 Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559–69. 55 Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608–10. 56 Aschner P, Kipnes MS, Lunceford JK et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632–7. 57 Vella A, Bock G, Giesler PD et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007; 56: 1475–80. 58 AACE. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 (Suppl. 1): 1–68. 59 NICE. National Institute for Clinical Excellence Clinical Guideines. Management of Type 2 Diabetes: Management of Blood Glucose. London: National Institute for Clinical Excellence, 2002. 60 CDA. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27 (Suppl. 2): S1–S116.
URI:	http://wrap.warwick.ac.uk/id/eprint/29124

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item